The 1964 trial of antihypertensive treatment I appreciate your commentary in the Journal of Human Hypertension in December 2004, and in particular your dedication. 1, 2 I was very pleased that you also referred to the paper by Leishman of 1961.
3 Despite its obvious defects, this was the first paper convincingly to demonstrate the eronmous benefits of antihypertensive therapy, particularly in respect of stroke, heart failure and renal failure in patients with nonmalignant hypertension. I believe this paper was never sufficiently acknowledged.
I accept your comments on the absence of a placebo group. All of the 61 patients included in the trial had sustained severe hypertension prior to inclusion. The only drugs available at that time capable of providing effective control of such hypertensionprincipally pentolinium, bethanidine, guanethidine, and later methyldopa -all produced of many severe side effects. It was therefore, obvious to the clinician which patients were receiving active drug treatment, so I concluded that the inclusion of a placebo group was of little purpose and would have delayed the initiation and completion of the trial. Clearly, with more modern, tolerable drugs, the inclusion of placebo group would be considered mandatory. 
